Article info

Download PDFPDF

Original article
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Authors

  1. Correspondence to Dr Nataliya Volkova, Vertex Pharmaceuticals Incorporated, Boston MA 02210, USA; Nataliya_Volkova{at}vrtx.com
View Full Text

Citation

Bessonova L, Volkova N, Higgins M, et al
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Publication history

  • Received April 11, 2017
  • Revised March 23, 2018
  • Accepted April 9, 2018
  • First published May 10, 2018.
Online issue publication 
July 13, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.